Form 4: Oragenics Director Fred Telling Acquires 65,000 Options

Director Fred Telling acquired 65,000 options in Oragenics Inc. on September 19, 2024, under the company's 2021 Equity Incentive Plan.

Summary

• Fred Telling, a director of Oragenics Inc. (OGEN), acquired 65,000 options to purchase common stock on September 19, 2024.
• The options were granted under the company's 2021 Equity Incentive Plan as part of the non-employee director compensation program.
• The exercise price of the options is $0.48, which is the closing price of Oragenics' stock on the grant date.
• The options vest immediately and expire on September 19, 2034.
• Following the transaction, Telling beneficially owns 65,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard compensation practice. The option grant itself is neither overwhelmingly positive nor negative.

Positives

• The immediate vesting of the options could incentivize the director to work towards the company's success.

Industry Context

This is a standard practice for compensating non-employee directors, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Option grants to non-employee directors are a common practice in publicly traded companies to align their interests with shareholders.
• The size of the grant and vesting schedule are typical for director compensation packages.

Stakeholder Impact

• The option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

Oragenics, OGEN, Director, Fred Telling, Options, Equity Incentive Plan, Beneficial Ownership, Form 4